Platinum-refractory germ cell tumors: an update on current treatment options and developments

Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT).

(2017) A. Jain et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: Phase II study.

(2017) Iwona Anna Skoneczna et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of pazopanib in chemo-resistant patients with germ cell tumors (GCT): First results of the open-label, single-group, phase II PAZOTEST-01 trial.

(2017) Patrizia Giannatempo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of everolimus in refractory testicular germ cell tumors

(2016) Michal Mego et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors

(2015) Y. Nieto et al.   ANNALS OF ONCOLOGY

Exome-wide Sequencing Shows Low Mutation Rates and Identifies Novel Mutated Genes in Seminomas

(2015) Ioana Cutcutache et al.   EUROPEAN UROLOGY

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Current chemotherapeutic approaches for recurrent or refractory germ cell tumors

(2015) Brent O׳Carrigan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Targeted therapies in germ cell tumors

(2015) Christian M. Squillante et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

(2014) David J. Vaughn et al.   CANCER

Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors

(2014) D. R. Feldman et al.   CLINICAL CANCER RESEARCH

Cisplatin resistance in germ cell tumours: models and mechanisms

(2014) C. Jacobsen et al.   Andrology

The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors

(2013) M. Juliachs et al.   CLINICAL CANCER RESEARCH

Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes

(2013) Andrea Necchi et al.   Clinical Genitourinary Cancer

Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis

(2013) G. Gandaglia et al.   EJSO

Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer

(2013) R. Koster et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Precision Oncology: An Overview

(2013) Levi A. Garraway et al.   JOURNAL OF CLINICAL ONCOLOGY

Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study

(2013) Rüdiger Wessalowski et al.   LANCET ONCOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Contemporary Management of Postchemotherapy Testis Cancer

(2012) Siamak Daneshmand et al.   EUROPEAN UROLOGY

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

(2011) K. Oechsle et al.   ANNALS OF ONCOLOGY

Long-Term Survival After Treatment with Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients with Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors

(2011) Karin Oechsle et al.   EUROPEAN UROLOGY

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

(2011) Anja Lorch et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer

(2011) Timothy A. Masterson et al.   UROLOGY

TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis

(2010) Darren R. Feldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

(2010)   JOURNAL OF CLINICAL ONCOLOGY

High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors

(2009) A. Lorch et al.   ANNALS OF ONCOLOGY

High DNA Methyltransferase 3B Expression Mediates 5-Aza-Deoxycytidine Hypersensitivity in Testicular Germ Cell Tumors

(2009) M. J. Beyrouthy et al.   CANCER RESEARCH

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

(2009) Darren R. Feldman et al.   INVESTIGATIONAL NEW DRUGS

Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors

(2009) Karin Oechsle et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Microsatellite Instability, Mismatch Repair Deficiency, andBRAFMutation in Treatment-Resistant Germ Cell Tumors

(2009) Friedemann Honecker et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Growing Teratoma Syndrome

(2009) David J. Vaughn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacotherapy of relapsed metastatic testicular cancer

(2008) C Kollmannsberger et al.   EXPERT OPINION ON PHARMACOTHERAPY

Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumours of the Testis

(2007) Axel Heidenreich et al.   EUROPEAN UROLOGY